Clinical Trials

  • Understanding and Diagnosing Allergic Disease in Twins

    The purpose of this study is to gain better understanding of how the immune system works in twins with and without allergic disease. Healthy volunteers are not specifically targeted. Healthy non-allergic study participants may be found through the course of evaluation for the presence of allergies.

    Now accepting new patients View Details
  • Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

    Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

    Now accepting new patients View Details
  • Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

    The objectives of this dose-finding study for the treatment of peanut allergy are:

    - To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize peanut-allergic subjects to peanut after 12 months of treatment.

    - To evaluate the safety of a long-term treatment with Viaskin Peanut.

    Investigator

    Now accepting new patients View Details
  • Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

    An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

    Investigator

    Now accepting new patients View Details
  • Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

    The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.

    Investigator

    Now accepting new patients View Details
  • Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

    Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.

    Investigator

    Now accepting new patients View Details
  • Genetic and Environmental Factors in the Response to Influenza Vaccination

    The purpose of the study is to investigate and compare the cell responses to influenza vaccination in monozygotic (identical) and dizygotic (fraternal) twins to determine the roles of genetics and environment in the response to flu vaccination.

    Now accepting new patients View Details
  • Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

    The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

    Investigator

    Now accepting new patients View Details
  • Safety Study of Viaskin Peanut to Treat Peanut Allergy

    This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.

    Now accepting new patients View Details

Please see a full listing of Stanford's clinical trials here.

Use the ClinicalTrials.gov directory to search among all government-funded clinical trials.